Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
ESMO Open
|
March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
S Gupta, M A Climent Duran, S S Sridhar, et al.
Urologic Oncology
|
October 11, 2023
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study
G H Ghelani, M Bou Zerdan, J Jacob, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
T Powles, S Tagawa, C Vulsteke, et al.
BMC Cancer
|
May 25, 2021
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2025
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis
J Hoffman-Censits, M Tsiatas, P M-H Chang, et al.
ESMO Open
|
June 11, 2025
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study
H R Robinson, S Lakritz, D C Pavlick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar, D E Castellano, P Grivas, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
European Urology Focus
|
February 19, 2022
Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54]
Maria Carmen Mir, Michele Marchioni, Homi Zargar, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
ESMO Open
|
March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
S Gupta, M A Climent Duran, S S Sridhar, et al.
Urologic Oncology
|
October 11, 2023
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study
G H Ghelani, M Bou Zerdan, J Jacob, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
T Powles, S Tagawa, C Vulsteke, et al.
BMC Cancer
|
May 25, 2021
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2025
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis
J Hoffman-Censits, M Tsiatas, P M-H Chang, et al.
ESMO Open
|
June 11, 2025
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study
H R Robinson, S Lakritz, D C Pavlick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar, D E Castellano, P Grivas, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
European Urology Focus
|
February 19, 2022
Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54]
Maria Carmen Mir, Michele Marchioni, Homi Zargar, et al.
Page
of 3